Category: PMCPA Case of the Week

Cases selected for the AskAnzal weekly PMCPA insight newsletter

8 Mar 2026

GSK voluntary admission: Avamys digital banners had illegible non-proprietary name (AUTH/3341/5/20)

GSK admitted two Avamys online banner ads had a non-proprietary name that was not readily readable in the…

8 Mar 2026

AUTH/3408/10/20: Anonymous non-contactable v Amgen (Blincyto) – No breach (prescribing information alleged out of date)

Anonymous complaint alleged Blincyto detail aid prescribing information was incorrect/out of date. Panel found complainant provided no supporting…

8 Mar 2026

AUTH/3476/2/21: Anonymous (contactable) v Leo Pharma – LinkedIn profile allegations (No breach after appeal)

Complaint alleged a Leo employee’s LinkedIn CV-style β€œExperience” section promoted medicines and used β€œsafe” improperly. Panel found some…

8 Mar 2026

Thornton & Ross webinar invite: sponsorship not clear at the outset (AUTH/3577/11/21)

A webinar invitation email appeared to come from an independent organisation and did not mention Thornton & Ross.…

8 Mar 2026

Accord: representative provided Methofill training devices without flagging paediatric Crohn’s use was off-label (AUTH/3682/8/22)

A rep supplied Methofill injector training materials to a children’s gastroenterology nurse without immediately stating paediatric Crohn’s use…

8 Mar 2026

ALK-AbellΓ³: Representative’s Facebook post promoted Jext (POM) to the public

An ALK-AbellΓ³ representative posted about Jext on Facebook with a link to the product website and urged people…

8 Mar 2026

AUTH/3829/9/23: Complainant v GSK β€” event website sponsorship declaration (no breach)

Complaint alleged GSK sponsorship of an HCP event wasn’t disclosed on the homepage or registration pages. Panel found…

8 Mar 2026

AUTH/2131/6/08: Community pharmacist v GrΓΌnenthal Ltd – interim data used to support comparative claims for Versatis

A pharmacist challenged comparative efficacy and tolerability claims for Versatis versus pregabalin/gabapentin. The Panel found interim data and…

8 Mar 2026

AUTH/2270/10/09: Allergan v Merz Pharma β€” β€œAt least as effective as Botox” claim based on non-inferiority studies

Merz’s exhibition claim that Xeomin was β€œat least as effective as Botox” was ruled misleading because the cited…

8 Mar 2026

Flynn Pharma: competitor disparagement in rep training and discussion about Abstral during Actiq promotion (AUTH/2316/5/10)

A palliative medicine consultant complained about an Actiq rep’s comments on competitor Abstral. The Panel found misleading/disparaging competitor…

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training